{"id":"NCT01144338","sponsor":"AstraZeneca","briefTitle":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus","officialTitle":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-18","primaryCompletion":"2017-04-21","completion":"2017-04-24","firstPosted":"2010-06-15","resultsPosted":"2018-08-08","lastUpdate":"2018-08-08"},"enrollment":14752,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Exenatide Once Weekly","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Exenatide Once Weekly","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.","primaryOutcome":{"measure":"Primary Efficacy Outcome MACE Events","timeFrame":"Time to first event. Information collected during study period (anticipated to be up to 7.5 years).","effectByArm":[{"arm":"Placebo","deltaMin":905,"sd":null},{"arm":"Exenatide Once Weekly","deltaMin":839,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.061"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":629,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Germany","Hong Kong","Hungary","Israel","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39963952","39358806","38922488","35761271","34813910","32098501","31882409","31806653","31752517","31640705","31542942","31010875","30371301","29693361","28910237","28454792","26995376","22566747"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_bcb109_csp_amendment_6_updated_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_SAP_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3675&filename=d5551c00003_CSP_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1222,"n":7372},"commonTop":[]}}